Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.33 |
| ▸ | FURIN | P09958 | 2/20 | 0.33 |
| ▸ | FAP | Q12884 | 3/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24451076 | 0.94 | FURIN (0.35) | DGAT1FOLH1MAP1LC3BSIRT2SIRT1 | |
| SCHEMBL22541319 | 0.88 | DGAT1 (0.35) | DGAT1FOLH1MAP1LC3BSIRT2SIRT1 | |
| SCHEMBL24451140 | 0.85 | DGAT1 (0.33) | DGAT1FOLH1MAP1LC3BSIRT2SIRT1 | |
| SCHEMBL24451211 | 0.85 | DGAT1 (0.33) | DGAT1FOLH1MAP1LC3BSIRT2SIRT1 | |
| SCHEMBL24479338 | 0.85 | FURIN (0.34) | DGAT1FOLH1MAP1LC3BSIRT2SIRT1 | |
| SCHEMBL24479319 | 0.85 | DGAT1 (0.33) | DGAT1FOLH1MAP1LC3BSIRT2SIRT1 | |
| SCHEMBL24450764 | 0.84 | FAP (0.33) | DGAT1FOLH1MAP1LC3BSIRT2SIRT1 | |
| SCHEMBL23330073 | 0.83 | FAP (0.37) | DGAT1FOLH1MAP1LC3BFURINFAP | |
| SCHEMBL24472555 | 0.80 | FAP (0.32) | DGAT1FOLH1MAP1LC3BSIRT2SIRT1 | |
| SCHEMBL22597659 | 0.79 | FAP (0.37) | DGAT1FOLH1MAP1LC3BFURINFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160887-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160887-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, NCL, PBRM1 | DGAT1 4804/4885FOLH1 2026/4885MAP1LC3B 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.